PDF(Pubmed)
Abstract：
UNASSIGNED: To study the impact of the novel coronavirus disease-2019 (COVID-19) pandemic on incidence, seasonal variation, clinical presentation, and disease outcome of epidemic retinitis (ER) and to compare clinical outcomes with positive and negative COVID-19 serology.
UNASSIGNED: This is a retrospective, observational study conducted at a tertiary eye care hospital from August 2020 to June 2022. A graph of ER cases against the month of presentation was compared with the graph of the COVID-19 pandemic in the same region. Cases presented before COVID-19 vaccination, with positive COVID-19 serology (Group 1) were compared with cases with negative serology (Group 2).
UNASSIGNED: One hundred and thirty-two cases of ER were seen. The least number of cases were seen during and immediately after the peak of the pandemic (May 2021-August 2021). COVID-19 serology was positive in 13 (22 eyes)/60 (21.6%) unvaccinated cases. Along with COVID-19, positive serology for other ER etiologies was seen in 5/13 cases (38.4%). All patients received oral doxycycline with/without steroids. Groups 1 and 2 included 22 and 21 eyes of 13 cases each. Macular edema resolved in 43.6 and 32 days in groups 1 and 2, respectively. Retinitis resolved at 1 month in both groups. Corrected distant visual acuity was 20/50 and 20/70 at the presentation, which improved to 20/20 and 20/25 in groups 1 and 2, respectively. Mean and median follow-up was 6 months and 4.5 months, respectively, in both groups. No complications or recurrences were seen.
UNASSIGNED: No significant impact of the COVID-19 pandemic on ER was observed.
UNASSIGNED: This is a retrospective, observational study conducted at a tertiary eye care hospital from August 2020 to June 2022. A graph of ER cases against the month of presentation was compared with the graph of the COVID-19 pandemic in the same region. Cases presented before COVID-19 vaccination, with positive COVID-19 serology (Group 1) were compared with cases with negative serology (Group 2).
UNASSIGNED: One hundred and thirty-two cases of ER were seen. The least number of cases were seen during and immediately after the peak of the pandemic (May 2021-August 2021). COVID-19 serology was positive in 13 (22 eyes)/60 (21.6%) unvaccinated cases. Along with COVID-19, positive serology for other ER etiologies was seen in 5/13 cases (38.4%). All patients received oral doxycycline with/without steroids. Groups 1 and 2 included 22 and 21 eyes of 13 cases each. Macular edema resolved in 43.6 and 32 days in groups 1 and 2, respectively. Retinitis resolved at 1 month in both groups. Corrected distant visual acuity was 20/50 and 20/70 at the presentation, which improved to 20/20 and 20/25 in groups 1 and 2, respectively. Mean and median follow-up was 6 months and 4.5 months, respectively, in both groups. No complications or recurrences were seen.
UNASSIGNED: No significant impact of the COVID-19 pandemic on ER was observed.
摘要：
■为了研究2019年新型冠状病毒病（COVID-19）大流行对发病率的影响，季节性变化，临床表现,和流行性视网膜炎（ER）的疾病结局，并将临床结局与阳性和阴性COVID-19血清学进行比较。
■这是一个回顾，观察性研究于2020年8月至2022年6月在一家三级眼科护理医院进行.将ER病例与就诊月份的图表与同一地区的COVID-19大流行的图表进行了比较。COVID-19疫苗接种前出现的病例，将COVID-19血清学阳性的病例(第1组)与血清学阴性的病例(第2组)进行比较。
■发现了123例ER。在大流行高峰期间和之后（2021年5月至2021年8月）发现的病例最少。在13例（22只眼）/60例（21.6%）未接种疫苗的病例中，COVID-19血清学呈阳性。与COVID-19一起，其他内质网病因血清学阳性的病例为5/13(38.4%)。所有患者均口服多西环素，含/不含类固醇。第1组和第2组包括22只眼和21只眼，每组13例。第1组和第2组黄斑水肿分别在43.6天和32天消退。两组的视网膜炎在1个月时消退。演示时校正的远距视力为20/50和20/70，在第1组和第2组中分别提高到20/20和20/25。平均和中位随访时间为6个月和4.5个月，分别,在两组中。未见并发症或复发。
■未观察到COVID-19大流行对ER的显着影响。
■这是一个回顾，观察性研究于2020年8月至2022年6月在一家三级眼科护理医院进行.将ER病例与就诊月份的图表与同一地区的COVID-19大流行的图表进行了比较。COVID-19疫苗接种前出现的病例，将COVID-19血清学阳性的病例(第1组)与血清学阴性的病例(第2组)进行比较。
■发现了123例ER。在大流行高峰期间和之后（2021年5月至2021年8月）发现的病例最少。在13例（22只眼）/60例（21.6%）未接种疫苗的病例中，COVID-19血清学呈阳性。与COVID-19一起，其他内质网病因血清学阳性的病例为5/13(38.4%)。所有患者均口服多西环素，含/不含类固醇。第1组和第2组包括22只眼和21只眼，每组13例。第1组和第2组黄斑水肿分别在43.6天和32天消退。两组的视网膜炎在1个月时消退。演示时校正的远距视力为20/50和20/70，在第1组和第2组中分别提高到20/20和20/25。平均和中位随访时间为6个月和4.5个月，分别,在两组中。未见并发症或复发。
■未观察到COVID-19大流行对ER的显着影响。
